

Japan's PRISM BioLab partners with US-based startup Talus Bioscience for AI-based drug discovery

18 December 2025 | News

Collaboration combines Talus Bio's pioneering regulome profiling and AI-guided drug discovery platform with PRISM's innovative chemistry



Japan-based PRISM BioLab and US-based startup Talus Bioscience, Inc. have entered into a collaboration to discover novel inhibitors of transcription factor (TF) and protein-protein interaction (PPI) targets.

By combining Talus Bio's assay technologies for screening TF and PPI inhibitors in native cellular environment with PRISM's chemistry designed to target protein-protein interactions, companies are in a unique position to discover and develop drugs against these challenging targets.

Under the agreement, the companies will deploy PRISM's proprietary small-molecule libraries in Talus Bio's AI-guided regulome profiling screens to identify and optimise novel compounds against high-value TF and PPI targets. The collaboration aims to generate first-in-class chemical matter with direct functional effects on TF and PPI activity in live human cells.

Talus Bio and PRISM will share the costs of discovery research and development and any profits generated from out-licensing and commercialisation of discovered drug products.

This collaboration represents a pivotal step for both companies in establishing a systematic, scalable strategy to address TF and PPI targets. Together, PRISM and Talus Bio are creating a unified platform capable of revealing and modulating regulatory mechanisms that have remained undruggable for decades. By combining PRISM's PepMetrics® technology with Talus Bio's regulome profiling capabilities, the collaboration opens the door to therapies addressing diseases caused by previously undruggable targets.